$129 Million is the total value of Opus Point Partners Management, LLC's 52 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RPRXZ | Exit | REPROS THERAPEUTICS INCcall | $0 | – | -98,000 | -100.0% | -0.02% | – |
| CBYL | Exit | CARBYLAN THERAPEUTICS INC | $0 | – | -17,500 | -100.0% | -0.04% | – |
| INFI | Exit | INFINITY PHARMACEUTICALS INC | $0 | – | -30,000 | -100.0% | -0.16% | – |
| DPRX | Exit | DIPEXIUM PHARMACEUTICALS INC | $0 | – | -25,000 | -100.0% | -0.18% | – |
| DNAI | Exit | PRONAI THERAPEUTICS INC | $0 | – | -30,000 | -100.0% | -0.30% | – |
| TKAI | Exit | TOKAI PHARMACEUTICALS INC | $0 | – | -62,007 | -100.0% | -0.36% | – |
| NVAX | Exit | NOVAVAX INCput | $0 | – | -100,000 | -100.0% | -0.55% | – |
| NVAX | Exit | NOVAVAX INCcall | $0 | – | -100,000 | -100.0% | -0.55% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -30,000 | -100.0% | -0.61% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS | $0 | – | -100,000 | -100.0% | -0.68% | – |
| XNCR | Exit | XENCOR INC | $0 | – | -90,000 | -100.0% | -0.87% | – |
| NSTG | Exit | NANOSTRING TECHNOLOGIES INC | $0 | – | -102,200 | -100.0% | -0.99% | – |
| IBB | Exit | ISHARES TRnasdq biotec etf | $0 | – | -31,600 | -100.0% | -7.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.